Kikushige and Miyamoto reported that TIM-3 expression increased in CD34+/CD38- LSCs and blast cells in most AML patients, except for acute promyelocytic leukemia (M3), normal HSCs, and normal progenitors [10]. This evidence concerns the gene HAVCR2 and acute myeloid leukemia.